Market Overview

SHAREHOLDER ALERT: WeissLaw LLP Reminds AMAG, PTI, VRTU and GANS Shareholders About Its Ongoing Investigations

Share:

NEW YORK, Oct. 14, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) in connection with the proposed acquisition of the company by Covis Group S.à r.l.  Under the terms of the acquisition agreement, which is structured as a tender offer, AMAG shareholders will be entitled to receive $13.75 for each share of AMAG common stock that they own.  If you own AMAG shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/amag/  

Proteostasis Therapeutics, Inc. (NASDAQ:PTI)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Proteostasis Therapeutics, Inc. (NASDAQ:PTI) in connection with the company's proposed merger with Yumanity Therapeutics, Inc. ("Yumanity").  Under the terms of the agreement, PTI will acquire all outstanding shares of Yumanity in exchange for newly-issued shares of PTI common stock.  At close of the transaction, the newly combined entity will operate under the Yumanity name.  Following consummation, existing PTI shareholders will own only 32.5% of the new entity, with Yumanity shareholders retaining a 67.5% stake in the combined company.  If you own PTI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/proteostasis-therapeutics-inc/   

Virtusa Corporation (NASDAQ:VRTU)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Virtusa Corporation (NASDAQ:VRTU) in connection with the proposed acquisition of the company by Baring Private Equity Asia.  Under the terms of the acquisition agreement, VRTU shareholders will receive $51.35 for each share of VRTU common stock that they own.  If you own VRTU shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:   https://weisslawllp.com/virtusa-corporation/

GAINSCO, Inc. (OTC:GANS)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GAINSCO, Inc. (OTC:GANS) in connection with the proposed merger of the company with State Farm Mutual Automobile Insurance Company.  Under the terms of the acquisition agreement, the company's shareholders will receive $107.38 for each share of GANS common stock that they own.  If you own GANS shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/gainsco-inc/

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-amag-pti-vrtu-and-gans-shareholders-about-its-ongoing-investigations-301152762.html

SOURCE WeissLaw LLP

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com